Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$27.4 million","upfrontCash":"Undisclosed","newsHeadline":"T3 Pharma Raises 25M CHF to Advance Bacterial Cancer Therapy Through Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$509.0 million","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Expands Immuno-Oncology Portfolio with the Acquisition of Bacterial Cancer Therapy Specialist T3 Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by T3 Pharma

    Menu

    T3 Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              T3 Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Boehringer Ingelheim Expands Immuno-Oncology Portfolio with the Acquisition of Bacterial Cancer Therapy Specialist T3 Pharma

              Details:

              Through the acquisition, Boehringer expands its immuno-oncology portfolio and a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

              Deal Size: $509.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition November 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              T3 Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              T3 Pharma Raises 25M CHF to Advance Bacterial Cancer Therapy Through Clinic

              Details:

              T3 Pharma will use the funds primarily to progress its lead candidate, T3P-Y058-739, through clinical studies. The Phase 1/2 clinical study in solid tumors is planned to start in early 2021.

              Lead Product(s): T3P-Y058-739

              Therapeutic Area: Oncology Product Name: T3P-Y058-739

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

              Deal Size: $27.4 million Upfront Cash: Undisclosed

              Deal Type: Financing July 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY